Phase II / III CRO Services

Breakthrough — Radiopharmaceutical therapy represents a novel approach to treating cancer, utilising radioactive atoms to target and destroy malignant cells with precision, without affecting the patient’s healthy tissues. A field in which Aixial has emerged as a pioneer. 

Did you know that lung cancer is the most diagnosed cancer in the world? In 2022, it accounted for 12.4% of all new cancer cases and 18.7% of deaths. The 5-year survival rate for lung cancer has increased by 22% over the last 5 years due to advances in treatment. However, only 26% of cases are diagnosed at an early stage, when the survival rate is 61%.

Prostate cancer is on the increase globally, especially in men under the age of 50, and in 2022 there were 1.47 million new cases. The 5-year survival rate is close to 100%, largely thanks to advances in treatment and early detection.

Talents — The world of life sciences is vast and constantly evolving. It’s not enough to follow trends: you have to anticipate them, and to do that you need to bring together the best specialists. At Aixial Group, Stéphane Thérèse is well aware of this.

In recognition of Breast Cancer Awareness Month, Ashley Hunter, Head of Strategic Development and Delivery, offers valuable insights on the importance of early detection, the latest advancements and ongoing challenges in breast cancer research, and how Aixial Group is actively supporting the fight against breast cancer.

“We provide high-level expertise in a niche and critical area across the entire clinical supply chain flow, from the planning of the initial drug substance manufacturing to the Investigational Product reconciliation/destruction.”